Home

Emcure Pharmaceuticals Limited

NSE: EMCURE

₹1,927.60
+3.93%
EOD snapshot

About Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.

Healthcare · Drug Manufacturers - Specialty & Generic

Full scanner analysis & price chartMembers

Results

No scheduled results found for EMCURE.

Historical quarterly results aren't available in the current data feed.

Corporate Actions

No recent corporate actions for EMCURE.

Latest News · Emcure Pharmaceuticals Limited

Loading news…

More in Healthcare

All companies, by sector

Company overview assembled from NSE results / corporate-action feeds and market news. Not investment advice.